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Abstract
Background: Haematological malignancies are a common, heterogeneous and complex group of diseases that are 
often associated with poor outcomes despite intensive treatment. Research surrounding end-of-life issues, and 
particularly place of death, is therefore of paramount importance, yet place of death has not been formally reviewed in 
these patients.
Methods: A systematic literature review and meta-analysis was undertaken using PubMed to identify all studies 
published between 1966 and 2010. Studies examining place of death in adult haematology patients, using routinely 
compiled morbidity and mortality data and providing results specific to this disease were included. 21 studies were 
identified with descriptive and/or risk-estimate data; 17 were included in a meta-analysis.
Results: Compared to other cancer deaths, haematology patients were more than twice as likely to die in hospital 
(Odds Ratio 2.25 [95% Confidence Intervals, 2.07-2.44]).
Conclusion: Home is generally considered the preferred place of death but haematology patients usually die in 
hospital. This has implications for patients who may not be dying where they wish, and also health commissioners who 
may be funding costly end-of-life care in inappropriate acute hospital settings. More research is needed about 
preferred place of care for haematology patients, reasons for hospital deaths, and how these can be avoided if home 
death is preferred.
Background
Haematological malignancies are common, being the
fourth most frequently diagnosed cancer in both males
and females in economically developed regions of the
world [1-3]. Although traditionally regarded as lym-
phoma, leukaemia and myeloma, haematological malig-
nancies are, in fact, exceptionally heterogeneous, with the
World Health Organisation classification system recogn-
ising over 60 different clinical and pathological disease
subtypes [4]. This complexity is further reflected in the
widely varying clinical features, treatment pathways and
outcomes associated with these diseases [5]. Despite
recent advances in treatment, survival for some disease
subtypes may be poor, and in this context it is clear that
good end-of-life care is an issue that is of equal signifi-
cance as achieving cure [6]. Consequently, research sur-
rounding end-of-life issues and particularly place of death
is important, yet despite this, there is a distinct lack of
formal research in this area.
It is generally believed that the majority of people,
including haematology patients, would prefer to be cared
for and die at home [7-9]. In the United Kingdom (UK),
t h e  N a t i o n a l  E n d  o f  L i f e  C a r e  P r o g r a m m e  [ 1 0 ]  w a s
launched in 2004, with one of its aims being to ensure
individuals have more choice as to where they live and
d i e .  P u b l i c a t i o n  o f  t h e  E n d  o f  L i f e  C a r e  S t r a t e g y  [ 1 1 ]
brought together initiatives from this programme includ-
ing Advance Care Planning, Preferred Priorities for Care,
the Gold Standards Framework and Liverpool Care Path-
way for the Dying Patient, to ensure choice was available
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to patients and so enable them die in their preferred
place.
A number of individual studies have examined place of
death in patients with haematological malignancies [12-
31,48]. Although these report patients dying in hospital
more frequently than those with solid tumours, this has
never been formally reviewed. This review systematically
examines all studies of place of death in haematology
patients and includes a meta-analysis of risk estimates. It
also explores factors reported in the wider literature that
are considered to lead to hospital deaths in these patients.
F i n a l l y ,  f u r t h e r  r e s e a r c h  i s  s u g g e s t e d ,  w h i c h  w o u l d
improve understanding of end-of-life care and place of
death and could also be used to drive change in this com-
plex area.
Methods
PubMed was searched in January 2009 (with a final
search in March 2010) for all studies, in any language,
published between 1966 and 2009 and containing the
terms 'haematology', 'lymphoma', 'leukaemia', 'myeloma'
or 'cancer', combined with 'place of death', 'place of care'
or 'end-of-life' in the title, abstract or keywords. PubMed
titles were also searched for specific phrases including:
'place of death', 'death in hospital', 'nursing home death',
'hospice death', 'death at home', 'place end of life', 'dying in
hospital', 'dying home' and 'dying hospice'.
All identified abstracts were reviewed by two research-
ers and a scoring system used to select papers meeting
specific pre-determined criteria. One point was scored
for each of the following: examining place of death;
including patients with haematological malignancies;
including adults; obtaining information on place of death
from routinely compiled morbidity and mortality data;
and providing results specific to the haematology
patients. References of identified studies were also
searched and additional papers included as appropriate.
Studies of children ≤18 years were excluded due to the
different issues associated with place of death in this age
group in terms of disease types, clinical care, associated
infrastructure (for example hospice provision) and family
support.
The search identified 2,007 published reports (Figure
1). During the screening process, studies scoring 3 or less
were excluded from the abstract alone (n = 1,927). Studies
scoring 4 or 5, or with unclear scores (for example if the
cancer sites included were not specified in the abstract)
were retrieved for scrutiny (n = 80). Twenty-four publica-
tions meeting all the criteria were selected for final
screening and a further 3 were then excluded. This was
either because the data appeared elsewhere [32], or the
study was in an area where important cultural differences
influenced place of death to an extent not found in other
settings [33], or data discrepancies were identified mean-
ing that the original published material could not be used
[34]. The remaining 21 studies are included in this
review; and 17 presented data that could be included in a
meta-analysis, one of which gave data for 5 individual
countries. This equates to a total of over 30,150 haema-
tology patients - the number of patients was not given in
four studies, one of which was included in the meta-anal-
ysis [22].
Descriptive data, in terms of the percentage of hospital
deaths were extracted for all cancers and for haematolog-
ical malignancies where given. Risk-estimates for hospital
death, with 95% confidence intervals, were also extracted
or calculated if data were amenable. Descriptive data
were summarised and a meta-analysis of risk-estimates
created using Stata 10.0 Statistical Software, and pre-
sented in a meta-plot (Figure 2).
Results
In comparing haematological malignancies to other can-
cer deaths, it is evident that haematology patients are
more likely to die in hospital (Table 1). As shown in Fig-
ure 2 haematology patients are, in fact, more than twice
as likely to die in hospital compared to those with other
cancers (Odds Ratio 2.25 [95% Confidence intervals,
2.07-2.44] p < 0.0001). Studies examining death in other
areas, such as hospices, also found that those with hae-
matological disease were less likely to die in these places
compared to those with other cancers (Table 1)
[20,26,30].
Variation was seen in the type of haematological malig-
nancy included in individual studies, with some including
several diagnostic categories and others focusing on one
particular classification. However, results were again
found to be largely consistent across sub-groups. One UK
Figure 1 Study Selection Process.Howell et al. BMC Palliative Care 2010, 9:9
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study with a detailed sub-group analysis reported more
hospital deaths among all types of haematological malig-
nancy (62%) compared to other malignancies (41%) but
with some variation between subgroups [30]. For exam-
ple, greater proportions of hospital deaths were seen in
patients with acute myeloid leukaemia (67%) and chronic
lymphocyte leukaemia (67%). Interestingly, the propor-
tion of patients with acute lymphoblastic leukaemia dying
at home (31%) was similar to that seen for other cancers
(30%), as was the proportion with Hodgkin lymphoma
(27%).
Discussion
It is a challenging yet opportune time for practitioners
delivering end-of-life care, especially in the UK where
there is a drive to enable patients to be cared for and die
in the place of their choice. Our review clearly illustrates
that the majority of patients with a haematological malig-
nancy die in hospital. They are in fact more than twice as
likely to die in hospital as those with other cancers. Stud-
ies mostly originated from within Europe, the USA and
Australia and findings were generally consistent across
these areas. Given that home is usually considered to be
the preferred place of death [7,8], this has implications for
both patients, who may not be dying in their preferred
place, and also health commissioners, who may be fund-
ing costly end-of-life care in inappropriate, acute hospital
settings.
In order to ensure haematology patients receive appro-
priate end-of-life care, and are enabled to die in their pre-
f e r r e d  p l a c e ,  i t  i s  c r u c i a l  t h a t  a n  e v i d e n c e  b a s e  i s
established so that existing practices can be defined and
evaluated. In terms of understanding why hospital deaths
are so common, current explanations are often derived
from anecdote, case studies or qualitative research stud-
ies. Factors cited as leading to hospital death often
include the complex transition from an active or curative
approach to a palliative approach to care - a transition
Figure 2 Estimated risk of hospital death - haematological malignancy compared to non-haematolgical malignancy. NA = Not Available. * 
Denotes risk-estimate calculated from data reported in study.
p < 0.0001)
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Table 1: Summary of reported findings and proportion of hospital deaths for all cancers and haematological 
malignancies.
Study Country Dates of 
deaths
Total patients (% hospital deaths) Main findings
All cancers Haematological 
malignancy
Aabom, 2005 [12]* Denmark 01/96-12/98 4,092 (70) 129 (84) Compared to all other cancer deaths, 
patients dying from 'haematological' 
cancers (coding not specified) were 
more likely to die in institutions 
(hospital/nursing home).
Bruera, 2002 [13]* USA 09/97-08/98 1,466 (57) 206 (84) Compared to all other cancer deaths, 
patients dying from 'hematologic' 
(coding not specified) were more likely 
to die in hospital.
Bruera, 2003 [14]* USA 09/96-08/98 13,577 (51) 1,223 (NA) Compared to all other cancer deaths, 
patients dying from 'haematological' 
cancers (coding not specified) were 
more likely to die in hospital.
Cardenas-Turanzas, 
2006 [15]*
USA 1999-2000 866 (58) 146 (79) Compared to all other cancer deaths, 
patients dying from 'leukaemia and 
lymphoma' were more likely to die in 
hospital than elsewhere (home/nursing 
home/hospice).
Cohen, 2006 [16]* Belgium 2001 15,0008 (54) 1,109 (75) Compared to all other cancer deaths, 
patients dying from 'hematologic' 
cancers were more likely to die in 
hospital than home/care home/
elsewhere.
1Cohen, 2008 [17] * Belgium
Netherlands
Sweden
Scotland
England
Wales
2003
2003
2002
2003
2003
2003
14,632 (59)
38,181 (31)
21,294 (85)
15,145 (57)
127,346 (49)
8,419 (60)
1,143 (71)
2,981 (47)
1,996 (91)
1,053 (74)
10,107 (70)
575 (78)
Compared to all other cancer deaths, 
patients dying from 'hematologic 
malignancies' were more likely to die in 
hospital/care home than outside 
hospital. This was consistent across all 
countries included.
Costantini, 1993 [18]* Italy 01/86-12/90 12,315 (69) 828 (79) Compared to all other cancer deaths, 
patients dying from 'leukaemia-
lymphoma' were more likely to die in an 
institution (hospital/elderly care home).
Costantini, 2000 [19]* Italy 1991 17,597 (48) 1,192 (64) Compared to all other specified cancer 
deaths, patients dying from cancers of 
the 'haemopoietic system' were more 
likely to die in a hospital/elderly care 
home.
Davison, 2001 [20]* UK July-Dec 
1977/87/97
1,324 (47) 83 (75) Compared to all other cancer deaths, 
patients dying from cancer of the 
'lymphatic' and 'haemopoietic tissue' 
were more likely to die in hospital and 
less likely to die in a hospice.Howell et al. BMC Palliative Care 2010, 9:9
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Declich, 1991 [21]* Italy 01/85-12/88 970 (18) 112 (27) Compared to all other cancer deaths, 
patients dying from 'lymphoma' and 
'haematopoietic neoplasms' were more 
likely to die in hospital (with the 
exception of colon cancer).
Decker, 2006 [48] UK/USA 1995-1998 UK 59,604 (56) USA 
51,668 (74)
NA Compared to all other cancer deaths, 
patients dying from cancer of the 
'lymphatic' and 'haematopoietic' tissue 
aged ≥40 years were less likely to die at 
home (12% UK; 14% USA).
Gatrell, 2003 [22]* UK 1993-2000 6,900 (35) NA Compared to all other cancer deaths, 
patients dying from 'lymphatic system' 
cancer were more likely to die in 
hospital.
Higginson, 1998 [23] UK 1985-1994 1,344,187 (66) NA Compared to all other cancer deaths, 
patients dying from cancers of the 
'lymphatic' or 'haematological system' 
were less likely to die at home.
Hunt, 1996 [24]* Australia 1990 2,800 (NA) 260 (NA) Compared to all other cancer deaths, 
patients dying from 'haematological' 
cancers (coding not specified) were 
more likely to die in a Metropolitan 
Public Hospital.
Hunt, 2001 [25]* Australia 1990-1999 29,230 (55) 3,045 (NA) Compared to all other cancer deaths, 
patients dying from 'lymphoma', 
'multiple myeloma' and 'leukaemias' 
(coding not specified) were more likely 
to die in a Metropolitan Public Hospital.
Lock, 2005 [26] UK 1995-1999 315,462 (50) NA (66) Compared to all other cancer deaths, 
patients dying from 'lymphatic' and 
'haematopoietic' cancers aged ≥75 
years, were more likely to die in hospital 
and less likely to die in a hospice.
McCusker, 1983 [27]* USA 1976-1978 2,989 (70) 315 (82) Compared to all other cancer deaths, 
patients dying from 'leukaemia and 
lymphoma' (coding not specified) were 
more likely to die in an acute care 
hospital.
Polissar, 1987 [28]* USA 1968-1981 22,456 (61) 978 (73) Compared to other common cancers (9 
selected cancer sites) patients with 'non-
Hodgkin lymphoma' were the most likely 
to die in hospital.
Roder, 1987 [29] Australia 1981 & 1985 1,582 (37) NA (57) Compared to other common cancers (8 
selected sites), patients with 
'haematological malignancies' 
(leukaemia, lymphoma and myeloma) 
were more likely to die in a Metropolitan 
Public Hospital.
Table 1: Summary of reported findings and proportion of hospital deaths for all cancers and haematological 
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which is not always clear in haematology [6,35-38]. This
lack of clarity can arise because some haematological dis-
eases, such as myeloma and follicular lymphoma are con-
sidered incurable from diagnosis; thus all treatments,
although having the potential to substantially prolong life,
are essentially given with palliative intent from the outset.
The situation is further complicated by the increasing
number of salvage therapies available to patients, result-
ing in continued treatment even in the very late stages of
disease, a situation which may give rise to sentiments of
denial or the continued hope of a response, both in
patients and practitioners [13,36,39].
In the UK, initiatives such as Advanced Care Planning,
Preferred Priorities for Care and the Gold Standards
Framework [11] aim to provide patients with the oppor-
tunity to discuss the place of their death and plan where
they would prefer this to happen. However, the patient
pathway associated with haematological malignancy is
recognised as being complex and uncertain, with death
sometimes occurring suddenly, unexpectedly, or very
rapidly after diagnosis [26,39-41]. Also, certain treat-
ments, such as allogeneic bone marrow transplantations,
can be associated with a rapid change in the focus of care
from curative to palliative [42]. In contexts such as these
the opportunity to discuss place of death may not arise, or
may even be inappropriate. Such situations may lead to
difficulties estimating prognosis and concerns about the
inappropriate early withdrawal of treatment [38]. Failure
to recognise and respond to this transition may, however,
lead to a crisis management situation and an inappropri-
ate emergency hospital admission [41].
Further factors influencing place of death are the dis-
ease symptoms and the side effects of chemotherapy,
which our previous work on patient pathways has shown
can be intensive and prolonged [5]. The possibility of
complicating factors, including anaemia, bleeding and
infection, can result in the need for ongoing transfusion
of blood products, antibiotic and antifungal medication,
which may require long term hospitalisation, with death
in acute or intensive care settings often being reported
[13,32,35,36,43].
In some situations, an excess of hospital deaths among
haematological malignancy patients has been suggested
to reflect the fact that haematologists have limited links
with palliative care services. This lack of integration has
b e e n  r e c o g n i s e d  a s  a  p a r t i c u l a r  p r o b l e m  i n  A u s t r a l i a ,
[6,38,39,44,45] and has led to the UK [46] making recom-
mendations to promote links between these specialities.
However, because of the nature of their condition, hae-
matology patients are known to have a sustained and
intense relationship with their haematology team
[22,32,41]. Indeed, unlike patients with other types of
cancer, those in haematology are often managed through-
out the entire course of their illness, including the termi-
nal phase, within haematology [30]. Whilst this close
association may explain the apparent lack of palliative
care involvement it could also result in patients having
difficulty accessing community palliative care services or
hospice facilities - a situation which may lead to an inap-
propriate acute hospital admission for terminal care and
ultimately death [41].
Our review indicated a dearth of empirical research
exploring these issues, in particular the factors and cir-
cumstances either leading to emergency hospital admis-
sion at the end-of-life, or preventing hospital discharge
and the delivery of end-of-life care at home. This may for
example include a better understanding of the degree to
which dependence on blood product transfusions exists
and potential alternatives to receiving these products in
hospital [41]. Clearly, further work exploring the com-
plexity and duration of the patient pathway, variations in
the type and intensity of treatment and the transition
from active, life prolonging to palliative care would lead
to better understanding of end-of-life issues among hae-
matology patients.
End-of-life care is a complex, multi-disciplinary and
indeed multi-dimensional concept, with many interre-
lated themes that cannot be considered in isolation [47].
Ross, 2007 [30]* UK 1995-2000 31,812 (41) 2,638 (62) Compared to all other cancer deaths, 
patients dying from haematological 
malignancy (all diagnoses combined) 
were more likely to die in hospital and 
less likely to die in a hospice.
Saugo, 2008 [31]* Italy 2004 350 (75) 31 (87) Compared to all other cancer deaths, 
patients dying from 'haematological' 
cancers ≥50 years were more likely to die 
in hospital.
1 Data on place of death only given for hospital and care home combined with the exception of Sweden, where care home is not a registered 
category.
NA = not available; *Included in meta-analysis.
Table 1: Summary of reported findings and proportion of hospital deaths for all cancers and haematological 
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It includes the provision of care by multiple practitioners
(for example, clinicians and nurse specialists in haematol-
ogy, palliative care and other medical specialities); liaison
and interaction between different settings (primary and
secondary care, out of hours care, social care, care homes
and hospices) and services (NHS, voluntary and local
authority). Thus a greater understanding is also needed
about the broader organisation, management and deliv-
ery of end-of-life care for haematology patients. More
information is also needed about potential limiting fac-
tors, such as a lack of community facilities and resources
including hospice places, community staff, equipment or
training. Importantly, variations in place of death by hae-
matological subtype [30] emphasise the need to further
explore these differences by specific disease classifica-
tions.
Although existing research indicates that preferred
place of death is often home, it is important to recognise
that currently there is no empirical evidence to support
this in haematology and again this is an area where more
research is needed. If, as the literature suggests, patients
develop a strong relationship with their clinical haematol-
ogy team over the duration of their illness, and hospital is
regarded as a place where they feel secure and are most
likely to receive prompt medical attention, then hospital
may indeed be the preferred place of place of care and
death for some. Further research with patients and carers
is needed to develop detailed, clearer insight into these
issues.
Conclusion
Home is generally considered the preferred place of death
but haematology patients usually die in hospital. This has
implications for patients who may not be dying where
they wish, and also health commissioners who may be
funding costly end-of-life care in inappropriate acute hos-
pital settings. More research is needed about preferred
place of care for haematology patients, reasons for hospi-
tal deaths, and how these can be avoided if home death is
preferred.
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